Status:
COMPLETED
Pathophysiological Understanding and Treatment of PTSD: an rTMS Approach
Lead Sponsor:
University of Calgary
Collaborating Sponsors:
Defence Research and Development Canada
Conditions:
Stress Disorders, Post-Traumatic
Brain Injuries
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
In Canada, the prevalence of PTSD is approximately 12%, similar to Canadian military personnel. Current treatments for PTSD are limited in efficacy and durability - indicating a dire need for novel in...
Detailed Description
In Canada, the prevalence of PTSD is approximately 12%, similar to Canadian military personnel. However, a 2002 study of members of Canadian Armed Forces found there was a striking positive correlatio...
Eligibility Criteria
Inclusion
- Adult participants represent a typically developing nervous system as a more reliable target for this stage of research.
- The presence of a PTSD diagnosis made by a physician will ensure participants are experiencing significant symptomatology and may benefit from treatment.
- The cutoff score on the PCL-5 will ensure that participants are experiencing similar levels of symptoms to each other.
- Need to have tried at least two types of treatment in the past
Exclusion
- Significant past medical history including seizures, stroke, severe traumatic brain injury, or central nervous system cancers may interfere with our evaluation of treatment outcome and will be criteria for exclusion.
- Metal in head/neck/eye is a contraindication to safety in the MRI scanner and TMS protocol.
- Women who are pregnant will not be included in the study due to potential risk of seizure during TMS. To determine if a patient is pregnant we will ask when their last menstrual cycle occurred. If there is a possibility of pregnancy, we will ask the participant to follow-up with their family doctor to confirm. We will then ask the participant to provide a written note from their treating practitioner stating they are not pregnant.
- Active suicidality
- Wellbutrin or benzodiazepine intake of more than 200mg/day, or more than 15 mg of Zopiclone per day as these medications lower seizure threshold
- Trauma experienced less than a year ago and/or trauma experienced only as a child
- Drug and/or alcohol abuse within the last 3 months (diagnosed by Canadian guidelines)
- Diagnosed schizophrenia, untreated bipolar disorder, or psychosis
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 18 2022
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03840369
Start Date
June 1 2020
End Date
March 18 2022
Last Update
November 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Foothill Medical Centre
Calgary, Alberta, Canada